BioCentury | Jan 8, 2020
Clinical News

Applied Therapeutics eyes galactosemia submission based on biomarker data

...the agency on slowly progressing metabolic disorders. The company said Wednesday that AT-007, its CNS-penetrant aldose reductase...
...72 healthy volunteers, in whom there were no drug-related adverse events. Paul Bonanos, Associate Editor Applied Therapeutics Inc. Aldose reductase...
BioCentury | Mar 30, 2017
Distillery Therapeutics

Cancer

...survival. In two human metastatic basal-like breast cancer cell lines, aldose reductase knockdown or the generic aldose reductase...
...aldose reductase expression or vehicle. In an orthotopic xenograft mouse model of metastatic basal-like breast cancer, aldose reductase...
...aldose reductase knockdown or epalrestat decreased metastasis to the lung. Next steps could include testing other aldose reductase...
BioCentury | May 23, 2016
Clinical News

Diepalrestat choline: Completed Phase IIb enrollment

...Business: Neurology Molecular target: Aldose reductase Description: Extended-release diepalrestat, a cocrystal of epalrestat, a reversible aldose reductase...
BioCentury | Jul 27, 2009
Clinical News

QR-333: Final phase IIb data

...see BioCentury, May 11). Quigley Corp. (NASDAQ:QGLY), Doylestown, Pa. Product: QR-333 Business: Neurology Molecular target: Aldose reductase...
BioCentury | May 11, 2009
Clinical News

QR-333: Phase IIb data

...Quigley Corp. (NASDAQ:QGLY), Doylestown, Pa. Product: QR-333 Business: Neurology Molecular target: Aldose reductase Description: Topical formulation of...
BioCentury | Dec 4, 2006
Clinical News

QR-333: Phase IIb started

...up to 200 patients. Quigley Corp. (QGLY), Doylestown, Penn. Product: QR-333 Business: Neurology Molecular target: Aldose reductase...
BioCentury | Oct 2, 2006
Clinical News

QR-333: Phase IIb start

...patients with diabetic neuropathy. Quigley Corp. (QGLY), Doylestown, Penn. Product: QR-333 Business: Neurology Molecular target: Aldose reductase...
BioCentury | Apr 17, 2006
Product Development

Sangamo's window panes

...profiles. The problem is that the therapeutic window for such compounds, including NGF and certain aldose reductase...
...likely used a subtherapeutic dose, said Ando, because higher doses caused too much injection-site pain. Aldose reductase...
...rationale in diabetic neuropathy: elevated glucose in the peripheral tissues of diabetics is converted by aldose reductase...
BioCentury | Mar 13, 2006
Clinical News

QR-333: IND submitted

...dose range of QR-333. Quigley Corp. (QGLY), Doylestown, Penn. Product: QR-333 Business: Neurology Molecular target: Aldose reductase...
BioCentury | Mar 13, 2006
Clinical News

QR-333: IND submitted

...Neurology Product: QR-333 Description: Topical formulation of quercetin, ascorbyl palmitate and vitamin D3 Molecular target: Aldose reductase...
Items per page:
1 - 10 of 25